PREVENTION OF ADHESIONS AND EXCESSIVE SCAR FORMATION USING ANGIOGENESIS INHIBITORS

Abstract: A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed. For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology.

Description: PREVENTION OF ADHESIONS AND EXCESSIVE SCAR FORMATION USING ANGIOGENESIS INHIBITORS Background of the Invention The present invention relates to methods for the prevention of adhesions, excessive scar formation and other types of abnormal proliferation of tissue using angiogenesis inhibitors. Scars are the result of wounds that have healed, lesions due to diseases, or surgical operations. Hypertrophic and keloid scars occur when the tissue response is out of proportion to the amount of scar tissue required for normal repair and healing. A keloid scar is a raised, firm, thickened red scar that exceeds the boundary of the injury and may grow for a prolonged period of time. The increase in scar size is due to deposition of an increased amount of collagen into the tissue. African-Americans are genetically prone to developing keloids. Keloid development has been associated with different types of skin injury including surgery, ear piercing, laceration, burns, vaccination or inflammatory process. Common sites are earlobes and the upper trunk and extremities. Surgical removal of keloids alone has been associated with a recurrence rate of 45% to 100% . The problem ot excessive scar formation that manifests itself clinically is a multi-billion dollar problem. For example, intra-abdominal adhesions results in a very significant morbidity and mortality in every surgery practice. Greater than 400,000 hospital admissions in the United States per year are for treatment of pelvic adhesions following surgery. Repeat surgery can greatly aggravate scarring. There is no effective treatment to prevent adhesions, although numerous different technologies have been tried, including application of barriers which are designed to avoid direct tissue to tissue interactions, and administration of immunosuppressants to decrease inflammatory reactions. Currently there is only one product approved by the FDA for intra- abdominal and one product approved by the FDA for pelvic adhesions. These are principally mechanical barriers to adhesion formation. They are only minimally effective clinically and there remains a huge demand for an alternative. Keloids have been treated with injection of corticosteroid into the scar, by laser therapy, and by administration of pharmacologic agents that interfere with collagen synthesis. Numerous treatments after excision have been used, such as postexcisional injections of corticosteroids or interferon, silicone sheeting, radiotherapy, and pressure splints or garments. See, for example, Berman, et al., J. Am. Acad. Dermatol. 33, 117-123 (1995); Pulton, Dermatol. Surg. 21, 947-951 (1995); Cosman. et al. , Plast. Reconstr. Surg. 53, 540-543 (1974); Rockwell, et al., Plast. Reconstr. Surg. 827-835 (1989); Griffin, et al.. Plast. Reconstr. Surg. 46, 145-150 (1970); Bisley, et al. , J. Am. Acad. Dermatol. 35, 113-114 (1996); Klumper, et al. , J. Acad. Dermatol. 31. 225-231 (1994); Larrabee. et al.. Arch. Otolarvngol. Head Neck Surg. 116, 1159-1162 (1990); Darzi, et al. , J. Plast. Surg. 45. 374-379 (1992); and Berman, et al. , J. Am. Acad. Dermatol. 37, 755-757 (1997). It is therefore an object of the present invention to provide a treatment for the prevention of excessive scarring and adhesions, without inhibition of wound healing. Summary of the Invention A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagiUol derivative like 0- chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as inocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure The inhibitors can be administered systemically and/or locally or topically, as needed For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology Brief Description ot the Drawings Figure 1 is a graph ot endogenous basic fibroblast growth factor (bFGF) (pg/cm2) over time (days alter wounding) ol mice treated with TNP-470 (solid circles) and controls that were not treated (open circles) Figure 2 is a graph ol percent wounds open over time (days alter wounding) lor mice treated with TNP-470 lor dillerent dosage regimes pretreatment days -60 to day 0. treated with TNP-470 days 5 to 18, treated with TNP-470 days 0 to 18, and treated with TNP-470 days 0. 2 and 4 Figure 3 is a graph ol breaking strength (tensile strength) ol linear wounds alter systemic administration ot TNP-470 days -20 to 0, davs 0 to 4, days 0 to 12, days 5 to 12, and control, measured on days 4, 7 and 12 alter wounding Detailed Description ol the Invention It has been discovered that excessive scar tormation and adhesions can be prevented or inhibited by administration ol an eliective amount ol anti-angiogenesis inhibitors Primate skin and solt tissue does not the regenerate Instead function is restored by the deposition ol new connective tissue, a scar The extent ol scarring is proportional to and related to the severity ol tissue loss (in terms ol volume and depth) Commonly, a deep wound involving a significant loss of dermis will heal with the deposition ol excess scar, a hypertrophic scar Another lorm ol excess scarring which is much less common is the keloid scar The keloid scar exceeds the boundaries ol the original injury Its intrusion into involved surrounding skin differs from that of a hypertrophic scar which remains within the boundaries of the original injury Another difference that distinguishes these abnormal scars is the presence of nodules in hypertrophic scars and their absence in keloids Both abnormal scar conditions are characterized by the excess deposition ol connective tissue, composed of a relatively high density of cells, and increased volume ol connective tissue matrix and an increased vascular supply resulting Irom increased number ol vessels Evidence gathered by laser Doppler blood flow monitoring demonstrated that hypertrophic scars developed as a consequence ol a delect in the remodeling phase ol repair (Ehrlich. H P , Kelley, S F (1992) Plast Reconstr Surg 90 993-998) No evidence was lound that supported that the hypertrophic scar was the uninterrupted continuation ol the proliferative phase ot repair Keloid scars also exhibit a high density ot blood vessels and enhanced circulation within the connective tissue scar tissues (Ehrlich. H P , et al (1994) Am J Pathol 145 105-113) Therefore, diminishing blood supply or preventing the development ol an increased blood supply with a higher density ol blood vessels, will block and retard the development ol excess scarring Scar tormation is the end product of the wound healing process This process occurs as a series ol overlapping phases that occur over a period ol time The initial phase called the lag phase is characterized by the deposition ol a transitional matrix mostly composed ol fibrin and an inflammatory response Following the lag phase, there is the proliferative phase ol repair which is characterized by the invasion by, and an increased density ol, mesenchymal cells, the syntheses and deposition ol a new connective tissue matrix, the completion ol re-epithehalization and the development ol a new blood supply The remodeling phase of repair terminates the proliferative phase and is characterized by a decrease in cell density, the better organization of the connective tissue matrix, and intact maturing epidermal surface and a decrease in the density of blood vessels It is clear that without the reduction in blood vessel density, the remodeling phase of repair is impaired and an immature, excessive fibrotic tissue is deposited within the healed wound site. The nutritional requirement of the mesenchymal cells in excess scar tissue requires an enhanced blood supply. Preventing the development of that blood supply will block the development of excess scarring. The control of angiogenesis represents the controls of the nutrient supply to the mesenchymal cells responsible for the synthesis and organization of the newly deposited connective tissue matrix of scar or fibrotic tissues. Without an adequate nutrient supply, limitations on the function and synthetic activity of mesenchymal cells occurs. Blocking the progression of angiogenesis will limit the nutrients supplied to mesenchymal cells and limit their metabolic activity. I. Therapeutic Compositions Anti-Angiogenesis Inhibitors Angiogenesis, the proliferation and migration of endothelial cells that result in the formation of new blood vessels, is an essential event in a wide variety of normal and pathological processes. For example, angiogenesis plays a critical role in embryogenesis. wound healing, psoriasis, diabetic retinopathy, and tumor formation, as reported by Folkman. J. Angiogenesis and its inhibitors. In: V. T. DeVita, S. Hellman and S. A. Rosenberg (eds.). Important Advances in Oncology, pp. 42-62, (J. B. Lippincott Co. , Philadelphia, 1985); Brem, H. , et al. , Brain tumor angiogenesis. In: P. L. Kornblith and M. D. Walker (eds.), Advances in Neuro-Qncology, pp. 89-101. (Future Publishing Co. , Mount Kisco, NY 1988); Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. , 285; 1182-1186 (1971); and Folkman, J. Successful treatment of an angiogenic disease. N. Engl. J. Med. , 320: 1211-1212 (1989). Identification of several agents that inhibit tumor angiogenesis has provided a conceptual framework for the understanding of angiogenesis in general. The inhibition of angiogenesis by certain steroids and heparin derivatives, reported by Folkman, J., et al. , Science 221: 719 (1983); and Murray, J. B. , et al. , Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J. Biol. Chem. , 261: 4154- 4159 (1986); led to studies elucidating the crucial role of remodeling of the extracellular matrix in angiogenesis. These agents apparently prevent angiogenesis by specifically disrupting the deposition and cross-linking of collagen, as reported by Ingber, D. , and Folkman, J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab. Invest.. 59: 44-51 (1989). The original description of angiogenesis inhibition in the presence of cartilage, reported by Brem. H. , et al.. J. Exp. Med. 141 : 427-439 (1975); Brem. H.. et al.. Extracellular Matrices Influences on Gene Expression pp. 767-772 (Academic Press. NY 1975); and Langer, R. , et al.. Science 70- 72 (1976); led to the isolation and purification from bovine cartilage of a protein fraction that not only inhibited angiogenesis but inhibited protease activity, described by Murray, J.B. , et al. , J. Biol. Chem. 261: 4154-4159 (1986). Subsequently, an extract derived from the vitreous of rabbits was shown to inhibit tumor angiogenesis by Brem, S. , et al.. Am. J. Ophthal. 84: 323-328 (1977). The demonstration that heparin alone enhanced the angiogenesis response buttressed the hypothesis that heparin produced by mast cells that had migrated to the tumor site facilitated the development of new capillaries, as reported by Kessler, D.A. , et al.. Int. J. Cancer 18:703- 709 (1976). Other studies on inhibition of angiogenesis have highlighted the importance of enzyme mediated remodeling of the extracellular matrix in capillary growth and proliferation (Folkman, J. , et al., Science 221 : 719- 725 (1983); Ingber, D. , et al. Lab. Invest. 59: 44-51 (1989); Folkman, J. , et al. , Science 243: 1490-1493 (1989); Krum, R. , et al., Science 230: 1375-1378 (1985); Ingber, D. , et al., Endocrinol. 119: 1768-1775 (1986); and Ingber, D. , et al. , J. Cell. Biol. 109: 317-330 (1989)). A number of investigators have reported that extracts ol cartilage, one of the lew avascular tissues in the body, can inhibit angiogenesis Eisentein. et al , Am J Pathol 81 , 1-9 (1987), Pau , et al , J Natl Cancer Inst 67.55-74 (1981), Brem and Folkman. J Exp Med 141. 427-439 (1975), Langer. et al , Science 193, 70-72 (1976), Langer, et al , Proc Natl Acad Sci USA 77, 431-435 (1980), and Lee and Langer, Science 221. 1185-1187 (1983) Several dilferent classes ol compounds have been determined to be uselul as inhibitors ol angiogenesis These include collagenase inhibitors such as metalloproteinases and tetracyclines such as minocyc ne, naturally occurring peptides such as endostatin and angiostatin. described lor example in U S patent No 5,733.876 to O'Reilly, et al , U S patent No 5.290,807. and U S Patent No 5.639.725. lungal and bacterial derivatives, such as lumagillin derivatives like TNP-470, the sulfated polysacchaπdes described in U S patent No 4.900.815 to Tanaka. et al and the protein-poiysacchaπdes ol U S patent No 4.975,422 to Kanoh. et al and synthetic compounds such as the 2.5-dιaryltetrahydrofurans ol U S patent No 5,629.340 to Kuwano. et al . aminophenylphosphonic acid compounds ol U S patent No 5.670.493 to Cordi. et al , the 3-substιtuted oxindole derivatives ol U S patent No 5.576.330 to Buzzetti. et al . and tha domides ol U S patent No 5.712.291 to D'Amato The antibiotics that are uselul as angiogenesis inhibitors are those having collagenase inhibitory activitv These include the tetracyclines and chemically modified tetracyclines (CMTs). and three ringed tetracychne homologs, that have the ability to inhibit collagenase but diminished antibacterial activity Examples ol commercially available tetracyclines include chlotetracyhne. demeclyeychne. doxycychne. lymecychne. methacychne, minocychne, oxytetracyc ne. rolitetracychne, and tetracychne The active salts, which are lormed through protonation ol the dimethylamino group on carbon atom 4. exist as crystalline compounds These are stabilized in aqueous solution by addition ol acid Minocychne, a semisynthetic tetracychne antimicrobial, described by Martell, M. J. , and Boothe, J. H. in J. Med. Chem. , 10: 44-46 (1967), and Zbinovsky, Y. , and Chrikian, G. P. Minocychne. In: K. Florey (ed.), Analytical Profiles ol Drug Substances, pp. 323-339 (Academic Press, NY 1977), the teachings of which are incorporated herein, has anticollagenase properties, as reported by Golub. L. M. , et al., , J_ Periodontal Res.. 18: 516-526 (1983); Golub. L. M. , et al. , J. Periodontal Res. 19: 651-655 (1984), Golub, L. M.. et al.. J. Periodontal Res. 20: 12- 23 (1985); and Golub. L. M., et al. , J. Dent. Res.. 66: 1310-1314 (1987) Minocychne. first described in 1967. is derived from the naturally produced parent compounds chlortetracychne and oxy tetracychne. The chemically moditied tetracyclines are described by U.S. Patent No 4.704,383 to McNamara. et al . 4.925.833 to McNamara. et al.. and 4.935,411 to McNamara. et al . the teachings of which are incorporated herein. Other exemplary anti-angiogenic compounds include penicillamine and some cytokines such as IL12 B. Carriers Pharmaceutical compositions containing the angiogenesis inhibitor are prepared based on the specilic application. Application can be either topical, localized, or systemic Any ol these compositions may also include preservatives, antioxidants. antibiotics, immunosuppressants. and other biologically or pharmaceutically effective agents which do not exert a detrimental effect on the normal tissue to be treated. Compositions lor local or systemic administration will generally include an inert diluent Solutions or suspensions used for parenteral, intradermal. subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols. glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediammetetraacetic acid, buffers such as acetates, citrates or phosphates and agents for the adjustment ot tonicity such as sodium chloride or dextrose The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic Systemic Carriers Inhibitors can be systemically administered either parenterally or enterally The composition can be administered by means of an infusion pump, tor example, of the type used for delivering insulin or chemotherapy to specific organs or tumors, by injection, or by depo using a controlled or sustained release lormulation In a prelerred systemic embodiment, drugs are administered orally, in an enteric carrier it necessary to protect the drug during passage through the stomach The angiogenic inhibitors can be administered systemically by injection in a carrier such as saline or phosphate bullered saline (PBS) or orally, in the case ol an inhibitor such as thahdomide, in tablet or capsule orm The tablets or capsules can contain any ol the lollowing ingredients, or compounds ol a similar nature a binder such as microcrystalline cellulose, gum tragacanth or gelatin, an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Pπmogel. or corn starch, a lubricant such as magnesium stearate or Sterotes, or a ghdant such as colloidal silicon dioxide When the dosage unit lorm is a capsule, it can contain, in addition to material ol the above type, a liquid carrier such as a tatty oil In addition, dosage unit forms can contain various other materials which modify the physical lorm ol the dosage unit, lor example, coatings ol sugar, shellac, or other enteric agents Local or Topical Carriers The angiogenic inhibitors can also be applied locally or topically, in a carrier such as saline or PBS, in an ointment or gel, in a transdermal patch or bandage, or controlled or sustained release formulation Local administration can be by injection at the site of the injury, or by spraying topically onto the injury. The inhibitor can be absorbed into a bandage for direct application to the wound, or released from sutures or staples at the site. Incorporation of compounds into controlled or sustained release formulations is well known. For topical application, the angiogenesis inhibitor is combined with a carrier so that an effective dosage is delivered, based on the desired activity, at the site of application. The topical composition can be applied to the skin for treatment of diseases such as psoriasis. The carrier may be in the form of an ointment, cream, gel, paste, foam, aerosol, suppository, pad or gelled stick. A topical composition for use of an ointment or gel consists of an effective amount of angiogenesis inhibitor in a ophthalmically acceptable excipient such as buffered saline, mineral oil. vegetable oils such as corn or arachis oil. petroleum jelly, Miglyol 182. alcohol solutions, or liposomes or liposome-like products. In a preferred form for controlled release, the composition is administered in combination with a biocompatible polymeric implant which releases the angiogenesis inhibitor over a controlled period of time at a selected site. Examples of preferred biodegradable polymeric materials include polyanhydrides, polyorthoesters. polyglycolic acid, polylactic acid, polyethylene vinyl acetate, and copolymers and blends thereof. Examples of preferred non-biodegradable polymeric materials include ethylene vinyl acetate copolymers. These can be prepared using standard techniques as microspheres, microcapsules, tablets, disks, sheets, and fibers. C. Other Therapeutic Agents which can be Administered in Combination The angiogenic inhibitors can be administered alone or in combination with other treatments. For example, the inhibitors can be administered with antibiotics, cytokines, and antiinflammatories such as cortisone, and/or other types of angiogenic inhibitors. Other combinations will be apparent to those skilled in the art. In a preferred embodiment for prevention of adhesions, the angiogenesis inhibitor is administered with a barrier, such as methylcellulose or other polymeric material, either topically at the time ol surgery or incorporated into the barrier, which is inserted at the time ol surgery In some cases the combination therapy will be achieved through the selection ol the angiogenesis inhibitor, lor example, minocychne. which both inhibits collagenase and is an antibiotic One ol the causes ol the failure ol intestinal anastamosis is the breakdown ol connective tissue by enhanced collagenase activity The inhibition ol this collagenase activity may be beneficial or improve the outcome ol these surgical procedures II Methods ol Treatment A Disorders to be Treated The angiogenic inhibitors can be used to prevent or inhibit excessive scar tormation. especially hypertrophic scars and keloid scars, and adhesions, especially lntra-peπtoneal or pelvic adhesions such as those resulting alter open or laproscopic surgery, and burn contractions Other conditions which should be beneliciallv treated using the angiogenesis inhibitors include prevention ol scarring lollowing transplantation, cirrhosis ol the liver, pulmonary iibrosis lollowing acute respiratory distress syndrom or other pulmonary Iibrosis ol tne newborn, implantation ol temporary prosthetics. and adhesions after surgery between the brain and the dura B Effective Dosages and Treatment Regimes The angiogenesis inhibitor will typically be administered either at the time ol surgery or shortly therealter. usually within one week, except in those cases where the injury is to the skin or other superlicial suriace and can be readily accessed lollowing the injury or surgery A particular example ol the latter is in the treatment ol wounds It is desirable to treat exposed wounds ol the skin alter there has been re-epitheliahzation ol the skin's suriace Wounds in normal healthy patients may close in as short as five to seven days, in deep burn patients wounds may take three to six weeks to close. Since the remodeling phase of repair occurs after the wound is closed, and there is a new epidermal surface, preventing the new growth of blood vessels at this time is not detrimental to the healing process and will reduce normal skin-like barrier function no more than that of a normal scar. In the case ol adhesions, the deposition of connective tissue between normal anatomical structures is unnecessary. Hence preventing the development of an enhanced blood supply to that tissue would not be detrimental to the host. On the other hand, preventing the closure of an open wound could be detrimental to the host. Therefore the time of commencement of therapy would be different in preventing adhesions and preventing excess dermal scarring In the case of adhesions, therapy will start early, that is. soon alter procedures which lead to local trauma and the deposition ol a transitional matrix On the other hand, with skin injury, the healing process would continue and therapy would be withheld until the wound was closed, as demonstrated by an intact epidermal surface. The angiogenesis inhibitor is administered in a dosage and in a regimen that does not prevent wound healing, but does decrease the amount of blood vessel growth at the wound site to prevent or decrease lormation of high density cellular and connective tissue within the scar or outside ol the wound area (keloids) In order to have increased levels ol cells and deposited connective tissue one must have an increased nutritional supply via vasculaπzation Dosages will typically be in the same range as used lor inhibition ol tumor growth, but administered to a different class ol patients and for different time periods, since wound healing typically occurs over a much shorter time. Moreover, when administered topically or in a sustained release iormulation, the dosage may be lower in order not to prevent wound healing The present invention will be further understood by reference to the following non-limiting examples. Example 1 : Inhibition of Scar Formation TNP-470 interferes with blood vessel and collagen formation resulting in decreased adhesions. As demonstrated by the following data, TNP-470 results in the abolishment of intra-abdominal adhesions. Methods Full thickness mouse wounds were made in adult mice, the majority of whom were six to eight weeks old and some of whom were fourteen to sixteen weeks old. Mice were pretreated for sixty days with TNP-470, then wounds were made, and healing monitored. Mice were treated with 30 mg/kg TNP-470 administered subcutaneously every other day. Histological micrographs ot open mouse wounds harvested at 7, 12, and 17 days post excision were made The biopsies were fixed, embedded, sectioned and stained with hematoxylin and eosin. Results Examination ol 7-day untreated healing wound granulation tissue showed a high density ot blood vesselswith some large patent vessels. Examination ot 7-day TNP-470 treated healing wound granulation tissue showed a relatively lower density of blood vessels, with some having smaller patent vessels Examination ot a 12-day untreated closed wound showed granulation tissue under a re-epitheliahzed suriace with numerous patent blood vessels Examination ol a 12-day TNP-470 treated healing wound that is not completely closed, showed that granulation tissue under a re-epithelialized surface shows fewer vessels with smaller diameters. Examination ot a 17-day untreated healed wound showed mature granulation tissue with patent vessels, but a reduced density of mesenchymal cells. Examination ol a 17-day TNP-470 treated healed wound showed mature granulation tissue with a reduction in the number of vessels, but a continued higher density of mesenchymal cells. The histologic findings demonstrate that TNP-470 severely retarded scar tormation At 7 days the treatment group had a lower density ol blood vessels and reduced granulation tissue compared to untreated controls In contrast, mesenchymal cell infiltration was similar in treated compared to untreated animals At 12 days the open wounds in the controls were completely re-epitheliahzed and revealed a greater density ol patent vessels, compared to partially closed TNP 470-treated wound In addition. the density ol mesenchymal cells in the TNP-470 treated granulation tissue appeared greater than in the controls and the epidermal suriace was thicker in the treated group At 17 days, when both treated and untreated mouse wounds were closed, the density ol blood vessels remained elevated in the untreated mice, compared to the treated mice which had a lower density ol blood vessels In contrast, at day 17 alter wounding, the density ot mesenchymal cells and the thickness ol the epidermis was greater in TNP- 470 treated mice Thicker epidermis and greater density ol mesenchymal cells represent retarded scar maturation Thus inhibition ol angiogenesis by TNP-470 resulted in retarded wound closure by wound contraction and re-epithelia zation and also increased time required lor maturation ol granulation tissue Example 2 Inhibition ol Scarring during Wound Healing Further experiments were conducted to examine the role ol the angiogenic inhibitors in wound healing and prevention ol excessive scarring Methods Mice were treated essentially the same as described in Example 1 Results As demonstrated by Figure 1 , endogenous synthesis ol basic libroblast growth lactor in the wound is decreased alter treatment with the angiogenesis inhibitor, TNP-470 Treatment ol mice with the angiogenesis inhibitor TNP-470 resulted in an average ol 37% reduction ol bFGF concentration on day 10 after wound (p<0.05). This data suggests that one possible mechanism of TNP-470's ability to inhibit angiogenesis is as a consequence of the decreased amount of basic fibroblast growth factor in the wound. Histological analysis of the wounds in the control and treated mice compared contraction of full thickness wounds in mice treated with systemic TNP-470 (AGM 1470), every other day after the wound is made, with untreated mice. Treatment with TNP-470 every other day after the wound is made (at a dose identical to that which results in maximal tumor inhibition) causes a 5-day delay in the complete contraction of the wound. Figure 2 (n=440 mice) compares wound closure following different treatment regimes. TNP-470 inhibited or slowed wound healing by 5 days to full contraction. This was statistically significant. The wound healing remained inhibited if TNP-470 was given on post wound days 0, 2. 4. or post wound days 0, 2, 4. 6. 8, and 10. Figure 3 (n=280 mice)graphs breaking strength of linear wounds after systemic administration of TNP-470. Breaking strength was inhibited 36% on post wound day 7 and 43% on post wound day 12. This was statistically significant. The wounds were inhibited if TNP-470 was given on post wound days 0. 2, 4 or post wound days 0. 2, 4. 6, 8. and 10.

Claims: We claim: 1. A method to inhibit excessive scar formation and adhesions comprising administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. 2. The method of claim 1 wherein the angiogenesis inhibitor is administered systemically. 3. The method of claim 1 wherein the angiogenesis inhibitor is administered topically or locally at the site of a wound. 4. The method of claim 1 wherein the angiogenesis inhibitor is administered to prevent or inhibit formation of hypertrophic scarring. 5. The method of claim 1 wherein the angiogenesis inhibitor is administered to prevent or inhibit formation of keloid scarring. 6. The method of claim 1 wherein the angiogenesis inhibitor inhibits collagenase. 7. The method of claim 1 wherein the angiogenesis inhibitor is selected from the group consisting of endostatin and angiostatin. 8. The method of claim 1 wherein the angiogenesis inhibitor is thalidomide. 9. The method of claim 1 wherein the angiogenesis inhibitor is a fumigillin. 10. A composition for application to a wound comprising an angiogenesis inhibitor in a dosage formulation effective to prevent or inhibit formation of hypertrophic scars or keloid scars. 11. The composition of claim 10 wherein the angiogenesis inhibitor is in a pharmaceutically acceptable carrier for topical application of the inhibitor, selected from the group consisting of an ointment, gel, spray, and paste. 12. The composition of claim 10 wherein the angiogenesis inhibitor is thalidomide in a carrier for topical administration. 13. The composition of claim 10 wherein the angiogenesis inhibitor is in a controlled release formulation which releases an effective amount of angiogenesis inhibitor to prevent or inhibit hypertrophic scar or keloid scar formation over the time period required for healing of a wound. 14. The composition of claim 10 wherein the angiogenesis inhibitor is in a formulation delivering sustained release of an effective amount of angiogenesis inhibitor to prevent or inhibit hypertrophic scar or keloid scar formation over the time period required for healing of a wound. 15. The composition of claim 10 in a dosage not inhibiting normal wound healing.

Inventors: BREM HAROLD, EHRLICH JASON, FOLKMAN JUDAH, BREM, HAROLD, EHRLICH, JASON, FOLKMAN, JUDAH
Applicants: BREM HAROLD, EHRLICH JASON, FOLKMAN JUDAH, BREM, HAROLD, EHRLICH, JASON, FOLKMAN, JUDAH
Application year: 1998
Main classification: A61K31
IPC codes: A61K31, A61K38, A61K45, A61P17